MRTX - Mirati Therapeutics GAAP EPS of -$3.04 beats by $0.17 revenue of $13.69M beats by $0.07M
2023-08-08 16:48:54 ET
- Mirati Therapeutics press release ( NASDAQ: MRTX ): Q2 GAAP EPS of -$3.04 beats by $0.17 .
- Revenue of $13.69M (+155.4% Y/Y) beats by $0.07M .
- Cash, cash equivalents and short-term investments of approximately $779.4 million as of June 30, 2023. Net reduction in cash, cash equivalents and short-term investments for the second quarter of 2023 was $122.9 million.
- The Company expects 2023 net cash burn to annualize within a range of $560 million to $580 million.
For further details see:
Mirati Therapeutics GAAP EPS of -$3.04 beats by $0.17, revenue of $13.69M beats by $0.07M